Targets

NLRP3

7 articles

PharmacologyBritish Journal of Pharmacology

Radiation speeds up plaque growth through a macrophage mtDNA–cGAS–STING–NLRP3 loop

  • Ionising radiation worsened atherosclerosis in ApoE-knockout mice, with more pyroptosis-related gene expression in plaque macrophages.
  • Radiation drove mitochondrial DNA into the cytoplasm, activating cGAS/STING/TBK1; phosphorylated IRF3 then bound the NLRP3 promoter and raised its transcription.
  • Caspase-1 deletion or macrophage-specific cGAS knockdown blunted the radiation effect.
PointsBased on the abstract

The genetic arms are convincing for the mechanism, but nobody has yet shown a pharmacological intervention: a STING or NLRP3 inhibitor given after irradiation would tell us whether this is druggable or just explanatory. STING inhibitors also carry a theoretical risk for the very antitumour immunity radiotherapy relies on, so any translation has to protect the heart without blunting the tumour response.

PharmacologyBritish Journal of Pharmacology

Cul4B tags NLRP3 for ubiquitination and shields the lung in sepsis models

  • Cul4B fell in the lungs of two sepsis-induced acute lung injury mouse models; lung overexpression limited injury and inflammation, while myeloid-specific deletion worsened barrier damage.
  • Cul4B bound NLRP3 and promoted its ubiquitination, restraining inflammasome activation in THP-1 cells and in Cul4B-deficient macrophages.
  • MN-08, a small molecule reported earlier to protect against LPS-induced lung injury, raised Cul4B expression and suppressed NLRP3.
PointsBased on the abstract

An E3 scaffold that naturally removes NLRP3 is an appealing node, but raising a scaffold's expression pharmacologically is much harder than inhibiting an enzyme. How selective MN-08 is for Cul4B is the open question. So is whether protection survives when treatment starts after sepsis onset, the only setting that matters clinically, rather than as prophylaxis.

Medicinal ChemistryJournal of Medicinal Chemistry

Re-engineered MCC950 analog gives longer-lasting, orally exposed NLRP3 inhibition with cleaner tolerability

  • Tuning the lipophilic and solvent-facing portions of the sulfonylurea MCC950 gave F34, which keeps nanomolar cellular potency and spares the NLRC4 and AIM2 inflammasomes.
  • Docking and molecular dynamics place F34 in the MCC950 site; SPR shows direct, micromolar binding to NLRP3.
  • In mice F34 has a long half-life and very high oral bioavailability, and outperforms MCC950 in gout and chronic colitis models, with better tolerability and low hERG and CYP liabilities.
PointsBased on the abstract

Compared with MCC950 and the newer sulfonylurea-free NLRP3 chemotypes, F34 is a conservative edit: the acidic sulfonylurea core, and its liver-safety question, is still there. Docking plus SPR is thin for a binding-mode claim, so I'd want a cryo-EM or co-crystal structure with NLRP3, and chronic-dosing liver data, before believing the improved tolerability.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

NLRP3 autophagy-based degrader outlasts its parent inhibitor in colitis

  • Starting from an NLRP3 inhibitor known to engage both LC3 and NLRP3, the authors mapped the groups needed for NLRP3 binding and built bivalent autophagy-targeting degraders from it.
  • One lead degrader, M3, emerged as the strongest NLRP3 degrader in the series.
  • In a colitis model, M3 gave more lasting anti-inflammatory benefit than its inhibitor precursor, supporting degradation over inhibition for this disease.
PointsBased on the abstract

Degradation beating inhibition on durability is the expected payoff of removing the protein rather than occupying it. Starting from a dual LC3/NLRP3 binder is a smart shortcut, but I'd worry the LC3 handle is carried by the same pharmacophore. I'd want a clean separation of NLRP3 binding from LC3 binding and the exposure data.

Medicinal ChemistryACS Medicinal Chemistry Letters

Pyridazino-indoles replace the phenol in pyridazine NLRP3 inhibitors

  • Indole-fused pyridazines were developed to replace the phenol group of earlier phenol-pyridazine NLRP3 inhibitors.
  • Cryo-EM and modeling suggest the indole keeps the key contact with Ala228 in the binding site.
  • Two lead compounds reached low-nanomolar potency with good solubility and permeability, and were profiled in mouse pharmacokinetic studies.
  • hERG inhibition ended development, though the compounds remain useful in vivo tools; a reactive metabolite audit is also reported.
PointsBased on the abstract

Replacing the phenol with an indole-fused pyridazine removes phenol liabilities while keeping the Ala228 contact, and potency and solubility look healthy. The cautionary note is hERG ending a series this strong: did the flat, lipophilic fused ring cause it? I would treat these compounds as in vivo tools, not a template to copy without scrutiny.

PharmacologyBritish Journal of Pharmacology

Chemoproteomics finds a brain-penetrant covalent NLRP3 inhibitor at a new allosteric site

  • Chemoproteomic profiling was used to find a covalent NLRP3 inhibitor.
  • The compound is brain-penetrant and is described as binding a previously unreported allosteric pocket.
  • Only the title and issue details were accessible when this was written, so potency, selectivity and efficacy data are not covered.
PointsBased on the abstract

NLRP3 has plenty of reversible MCC950-type chemistry, so the interest here is a different pocket and a route in neuroinflammation via brain exposure. Covalent warheads in a CNS drug still need clean proteome-wide selectivity, and the residue targeted matters for resistance and species translation. A new pocket gives other groups a second place to design against.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Istradefylline-derived thienopyrimidinones give an oral NLRP3 inhibitor for colitis

  • The anti-Parkinsonian drug istradefylline showed modest NLRP3 inhibition, and optimizing it gave a thienopyrimidinone series.
  • Lead L22 was roughly tenfold more potent than istradefylline, bound the NLRP3 NACHT domain directly and blocked inflammasome assembly.
  • It was orally bioavailable, eased symptoms in a DSS colitis model and looked safe in acute and subacute toxicity studies.
PointsBased on the abstract

Starting from a marketed drug's off-target activity gives a head start on drug-likeness, and direct NACHT-domain binding is what you want to see. NLRP3 is a busy field, so the real test is how L22 compares with clinical-stage inhibitors on potency and brain or gut exposure.